Literature DB >> 33900575

No additive effects of peginterferon on the short-term improvement of liver histology by entecavir monotherapy in chronic hepatitis B patients.

Tatsuo Kanda1.   

Abstract

Entities:  

Keywords:  Add-on; Entecavir; HBV; HBsAg loss; Liver histology; Pegylated interferon-alpha; Tenofovir

Year:  2021        PMID： 33900575     DOI： 10.1007/s12072-021-10191-w

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


× No keyword cloud information.
  9 in total

1.  Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.

Authors:  Yumiko Tatsukawa; Masataka Tsuge; Yoshiiku Kawakami; Yuichi Hiyama; Eisuke Murakami; Mio Kurihara; Motonobu Nomura; Ken Tsushima; Takuro Uchida; Takashi Nakahara; Daiki Miki; Tomokazu Kawaoka; Hiromi Abe-Chayama; Michio Imamura; Hiroshi Aikata; Hidenori Ochi; C Nelson Hayes; Hiroiku Kawakami; Kazuaki Chayama
Journal:  Antivir Ther       Date:  2018

2.  Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study.

Authors:  S-Y Li; H Li; Y-L Xiong; F Liu; M-L Peng; D-Z Zhang; H Ren; P Hu
Journal:  J Viral Hepat       Date:  2017-11       Impact factor: 3.728

Review 3.  Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.

Authors:  Shiv K Sarin; Manoj Kumar; Mohammed Eslam; Jacob George; Mamun Al Mahtab; Sheikh M Fazle Akbar; Jidong Jia; Qiuju Tian; Rakesh Aggarwal; David H Muljono; Masao Omata; Yoshihiko Ooka; Kwang-Hyub Han; Hye Won Lee; Wasim Jafri; Amna S Butt; Chern H Chong; Seng G Lim; Raoh-Fang Pwu; Ding-Shinn Chen
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-12-15

4.  Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B.

Authors:  Akihiro Matsumoto; Shuhei Nishiguchi; Hirayuki Enomoto; Yasuhito Tanaka; Noboru Shinkai; Chiaki Okuse; Jong-Hon Kang; Takeshi Matsui; Shiho Miyase; Hiroshi Yatsuhashi; Shinya Nagaoka; Tatsuo Kanda; Masaru Enomoto; Ryoko Yamada; Naoki Hiramatsu; Satoru Saito; Koichi Takaguchi; Kiyoaki Ito; Tsutomu Masaki; Daisuke Morihara; Masataka Tsuge; Kazuaki Chayama; Fusao Ikeda; Tatehiro Kagawa; Yasuteru Kondo; Kazumoto Murata; Eiji Tanaka
Journal:  J Gastroenterol       Date:  2020-07-14       Impact factor: 7.527

5.  Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection.

Authors:  Osamu Yokosuka; Koichi Takaguchi; Shinichi Fujioka; Michiko Shindo; Kazuaki Chayama; Haruhiko Kobashi; Norio Hayashi; Chifumi Sato; Kendo Kiyosawa; Kyuichi Tanikawa; Hiroki Ishikawa; Nobuyuki Masaki; Taku Seriu; Masao Omata
Journal:  J Hepatol       Date:  2010-03-24       Impact factor: 25.083

6.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

Authors:  George K K Lau; Teerha Piratvisuth; Kang Xian Luo; Patrick Marcellin; Satawat Thongsawat; Graham Cooksley; Edward Gane; Michael W Fried; Wan Cheng Chow; Seung Woon Paik; Wen Yu Chang; Thomas Berg; Robert Flisiak; Philip McCloud; Nigel Pluck
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

7.  Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Authors:  Yun-Fan Liaw; Joseph J Y Sung; Wan Cheng Chow; Geoffrey Farrell; Cha-Ze Lee; Hon Yuen; Tawesak Tanwandee; Qi-Min Tao; Kelly Shue; Oliver N Keene; Jonathan S Dixon; D Fraser Gray; Jan Sabbat
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Leukocyte cell-derived chemotaxin 2 promotes the development of nonalcoholic fatty liver disease through STAT-1 pathway in mice.

Authors:  Jinghua Wang; Yishu Chen; Ran Pan; Chao Wu; Shenghui Chen; Lan Li; Youming Li; Chaohui Yu; Zhuo-Xian Meng; Chengfu Xu
Journal:  Liver Int       Date:  2021-02-23       Impact factor: 5.828

9.  Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.

Authors:  Zhigang Fu; Xiaowei Li; Jiaming Zhong; Xiaoxia Chen; Kunkun Cao; Ning Ding; Li Liu; Xiaoli Zhang; Jian Zhai; Zengqiang Qu
Journal:  Hepatol Int       Date:  2021-04-20       Impact factor: 6.047
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.